Search

Author/Creator Rea, D.

1. 1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study. (September 2015)

Authors:
Stein, R.C.; Makris, A.; Hughes-Davies, L.; Bartlett, J.M.S.; Marshall, A.; Hall, P.S.; Campbell, A.; Pinder, S.E.; Cameron, D.A.; Rea, D.; Earl, H.; MacPherson, I.; Poole, C.; Canney, P.; Francis, A.; Morgan, A.; Stallard, N.; Hulme, C.; McCabe, C.; Dunn, J.A.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S268
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. (1st October 2019)

Authors:
Quagliariello, V.; Passariello, M.; Coppola, C.; Rea, D.; Barbieri, A.; Scherillo, M.; Monti, M.G.; Iaffaioli, R.V.; De Laurentiis, M.; Ascierto, P.A.; Botti, G.; De Lorenzo, C.; Maurea, N.
Journal:
International journal of cardiology
Issue:
Volume 292(2019)
Page Start:
171
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. (August 2018)

Authors:
Derks, M.G.M.; Bastiaannet, E.; van de Water, W.; de Glas, N.A.; Seynaeve, C.; Putter, H.; Nortier, J.W.R.; Rea, D.; Hasenburg, A.; Markopoulos, C.; Dirix, L.Y.; Portielje, J.E.A.; van de Velde, C.J.H.; Liefers, G.J.
Journal:
European journal of cancer
Issue:
Volume 99(2018)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. Issue 1 (January 2021)

Authors:
Earl, H.M.; Hiller, L.; Dunn, J.; Macpherson, I.; Rea, D.; Hughes-Davies, L.; McAdam, K.; Hall, P.; Mansi, J.; Wheatley, D.; Abraham, J.E.; Caldas, C.; Gasson, S.; O'Riordan, E.; Wilcox, M.; Miles, D.; Cameron, D.A.; Wardley, A.
Journal:
Clinical oncology
Issue:
Volume 33:Issue 1(2021)
Page Start:
15
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. P700: TREATMENT-FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5-YEAR RESULTS OF DASFREE. (23rd June 2022)

Authors:
Shah, N. P.; García-Gutiérrez, V.; Jiménez-Velasco, A.; Saussele, S.; Rea, D.; Mahon, F.-X.; Levy, M. Y.; Gómez-Casares, M. T.; Mauro, M. J.; Sy, O.; Martin-Regueira, P.; Lipton, J. H.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
595
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS. (23rd June 2022)

Authors:
Apperley, J.; Kantarjian, H.; Deininger, M.; Abruzzese, E.; Cortes, J.; Chuah, C.; DeAngelo, D. J.; DiPersio, J.; Hochhaus, A.; Lipton, J.; Nicolini, F.; Pinilla-Ibarz, J.; Rea, D.; Rosti, G.; Rousselot, P.; Mauro, M.; Shah, N.; Talpaz, M.; Vorog, A.; Ren, X.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
602
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗